Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 5
2010 6
2011 10
2012 15
2013 17
2014 13
2015 21
2016 27
2017 30
2018 29
2019 24
2020 31
2021 41
2022 18
2023 16
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

266 results

Results by year

Filters applied: . Clear all
Page 1
The Future of Targeted Therapy for Leiomyosarcoma.
Denu RA, Dann AM, Keung EZ, Nakazawa MS, Nassif Haddad EF. Denu RA, et al. Cancers (Basel). 2024 Feb 26;16(5):938. doi: 10.3390/cancers16050938. Cancers (Basel). 2024. PMID: 38473300 Free PMC article. Review.
Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets.
Zhang B, Lewis W, Stewart CA, Morris BB, Solis LM, Serrano A, Xi Y, Wang Q, Lopez ER, Concannon K, Heeke S, Tang X, Raso G, Cardnell RJ, Vokes N, Blumenschein G, Elamin Y, Fosella F, Tsao A, Skoulidis F, Hume CB, Sasak K, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Tran H, Zhang J, Gibbons D, Vaporciyan A, Wang J, Park K, Heymach JV, Byers LA, Gay CM, Le X. Zhang B, et al. JTO Clin Res Rep. 2023 Dec 17;5(2):100623. doi: 10.1016/j.jtocrr.2023.100623. eCollection 2024 Feb. JTO Clin Res Rep. 2023. PMID: 38357092 Free PMC article.
Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.
Gordon MJ, Feng L, Strati P, Lee HJ, Hagemeister FB, Westin JR, Samaniego F, Marques-Piubelli ML, Vega Vazquez F, Parra Cuentas ER, Solis-Soto LM, Ma W, Wang J, Claret L, Averill B, Ibanez K, Fayad LE, Flowers CR, Green MR, Davis RE, Neelapu SS, Fowler NH, Nastoupil LJ. Gordon MJ, et al. Cancer. 2024 Mar 15;130(6):876-885. doi: 10.1002/cncr.35114. Epub 2023 Nov 20. Cancer. 2024. PMID: 37985359 Clinical Trial.
Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes.
Denu RA, Yang RK, Lazar AJ, Patel SS, Lewis VO, Roszik J, Livingston JA, Wang WL, Shaw KR, Ratan R, Zarzour MA, Bird J, Raza S, Akdemir KC, Rodon Ahnert J, Subbiah V, Patel S, Conley AP. Denu RA, et al. Clin Cancer Res. 2023 Dec 1;29(23):4844-4852. doi: 10.1158/1078-0432.CCR-23-1703. Clin Cancer Res. 2023. PMID: 37747813
Complete loss of TP53 and RB1 is associated with complex genome and low immune infiltrate in pleomorphic rhabdomyosarcoma.
Beird HC, Wu CC, Nakazawa M, Ingram D, Daniele JR, Lazcano R, Little L, Davies C, Daw NC, Wani K, Wang WL, Song X, Gumbs C, Zhang J, Rubin B, Conley A, Flanagan AM, Lazar AJ, Futreal PA. Beird HC, et al. HGG Adv. 2023 Jul 19;4(4):100224. doi: 10.1016/j.xhgg.2023.100224. eCollection 2023 Oct 12. HGG Adv. 2023. PMID: 37593416 Free PMC article.
Immune-based therapies in diffuse large B-cell lymphoma.
McCurry D, Flowers CR, Bermack C. McCurry D, et al. Expert Opin Investig Drugs. 2023 Jan-Jun;32(6):479-493. doi: 10.1080/13543784.2023.2230137. Epub 2023 Jul 6. Expert Opin Investig Drugs. 2023. PMID: 37394970
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.
Lachowiez CA, Loghavi S, Zeng Z, Tanaka T, Kim YJ, Uryu H, Turkalj S, Jakobsen NA, Luskin MR, Duose DY, Tidwell RSS, Short NJ, Borthakur G, Kadia TM, Masarova L, Tippett GD, Bose P, Jabbour EJ, Ravandi F, Daver NG, Garcia-Manero G, Kantarjian H, Garcia JS, Vyas P, Takahashi K, Konopleva M, DiNardo CD. Lachowiez CA, et al. Blood Cancer Discov. 2023 Jul 5;4(4):276-293. doi: 10.1158/2643-3230.BCD-22-0205. Blood Cancer Discov. 2023. PMID: 37102976 Free PMC article. Clinical Trial.
266 results